Search results for "Intravenous immunoglobulin"

showing 10 items of 16 documents

A Machine Learning Model to Predict Intravenous Immunoglobulin-Resistant Kawasaki Disease Patients: A Retrospective Study Based on the Chongqing Popu…

2021

Objective: We explored the risk factors for intravenous immunoglobulin (IVIG) resistance in children with Kawasaki disease (KD) and constructed a prediction model based on machine learning algorithms.Methods: A retrospective study including 1,398 KD patients hospitalized in 7 affiliated hospitals of Chongqing Medical University from January 2015 to August 2020 was conducted. All patients were divided into IVIG-responsive and IVIG-resistant groups, which were randomly divided into training and validation sets. The independent risk factors were determined using logistic regression analysis. Logistic regression nomograms, support vector machine (SVM), XGBoost and LightGBM prediction models wer…

PopulationMachine learningcomputer.software_genreLogistic regressionPediatricsProcalcitoninRJ1-570Medicinerisk factorseducationOriginal Researcheducation.field_of_studyKawasaki diseasebusiness.industryRetrospective cohort studyNomogrammedicine.diseaseSupport vector machineprediction modelmachine learningPediatrics Perinatology and Child HealthKawasaki diseaseArtificial intelligencebusinesscomputerintravenous immunoglobulin resistancePredictive modellingFrontiers in Pediatrics
researchProduct

The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update

2014

This guideline is the result of a systematic literature review using the 'Grading of Recommendations Assessment, Development and Evaluation' (GRADE) methodology and a structured consensus conference held on 28 and 29 November 2012, in Berlin. It is a joint initiative of the Dermatology Section of the European Academy of Allergy and Clinical Immunology (EAACI), the EU-funded network of excellence, the Global Allergy and Asthma European Network (GA(2)LEN), the European Dermatology Forum (EDF), and the World Allergy Organization (WAO) with the participation of delegates of 21 national and international societies. Urticaria is a frequent, mast cell-driven disease, presenting with wheals, angioe…

Allergymedicine.medical_specialtyhivesImmunologylcsh:Medicine610 Medicine & healthDermatologyDiseaseurticariaimmune system diseaseslcsh:DermatologyHumansImmunology and AllergyMedicinemedia_common.cataloged_instanceEuropean unionskin and connective tissue diseaseswhealAsthmamedia_common2403 ImmunologyAcute urticariaAngioedemabusiness.industryangioedemalcsh:RConsensus conferenceangioedema; consensus; hives; urticaria; wheal; Humans; Urticaria10177 Dermatology ClinicGuidelinelcsh:RL1-803angioedema consensus hives urticaria wheal CHRONIC IDIOPATHIC URTICARIA QUALITY-OF-LIFE SERUM SKIN-TEST DELAYED PRESSURE URTICARIA DOSE INTRAVENOUS IMMUNOGLOBULIN ANTIIMMUNOGLOBULIN-E THERAPY RESISTANT CHRONIC URTICARIA RANDOMIZED CONTROLLED-TRIAL ULTRAVIOLET-B PHOTOTHERAPY WORLD-HEALTH-ORGANIZATIONmedicine.diseaseDermatologySystematic reviewconsensusFamily medicine2723 Immunology and Allergymedicine.symptombusinessAllergy
researchProduct

Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study

2002

A questionnaire-based retrospective clinical and immunological survey was conducted in 73 males with a definite diagnosis of X-linked agammaglobulinemia based on BTK sequence analysis. Forty-four were sporadic and 29 familial cases. At December 2000, the patients' ages ranged from 2 to 33 years; mean age at diagnosis and mean duration of follow-up were 3.5 and 10 years respectively. After the mid-1980s all but 2 were on intravenous immunoglobulin (IVIG) substitution therapy, with residual IgG >500 mg/dl in 94% of the patients at the time of enrollment. Respiratory infections were the most frequent manifestation both prior to diagnosis and over follow-up. Chronic lung disease (CLD) was prese…

Lung DiseasesAdultMalePediatricsmedicine.medical_specialtyGenetic Linkage; Agammaglobulinemia; Humans; Infant Newborn; Protein-Tyrosine Kinases; Child; Child Preschool; X Chromosome; Immunoglobulins Intravenous; Lung Diseases; Adult; Cohort Studies; Chronic Disease; Follow-Up Studies; Adolescent; Mutation; Maleclinical featuresX ChromosomeX-linked agammaglobulinemiaAdolescentGenetic LinkageImmunologyX-linked agammaglobulinemiaImmunoglobulinsX-linked agammaglobulinemia; infections; intravenous immunoglobulin; BTK mutationSepsisCohort StudiesAgammaglobulinemiaImmunopathologyintravenous immunoglobulinEpidemiologymedicineAgammaglobulinaemia Tyrosine KinaseImmunology and AllergyHumansinfectionsChildPreschoolSettore MED/38 - Pediatria Generale e SpecialisticaBTK mutationsbusiness.industryChronic sinusitisInfant NewbornMeningoencephalitisImmunoglobulins IntravenousInfantProtein-Tyrosine Kinasesmedicine.diseaseNewbornBTK mutationagammaglobulinemia; clinical features; BTK mutationsChild PreschoolChronic DiseaseMutationbusinessIntravenousMeningitisCohort studyFollow-Up Studies
researchProduct

Prognostic Factors of Death in 151 Adults With Hemophagocytic Syndrome: Etiopathogenically Driven Analysis.

2018

Objective: To characterize the etiologies and clinical features at diagnosis of patients with hemophagocytic lymphohistiocytosis (HLH) and correlate these baseline features with survival using an etiopathogenically guided multivariable model. Patients and Methods: The Spanish Group of Autoimmune Diseases HLH Study Group, formed in 2013, is aimed at collecting adult patients with HLH diagnosed in internal medicine departments between January 3, 2013, and October 28, 2017. Results: The cohort consisted of 151 patients (91 men; mean age, 51.4 years). After a mean follow-up of 17 months (range, 1-142 months), 80 patients died. Time-to-event analyses for death identified a worse survival curve f…

medicine.medical_specialtymedicine.medical_treatmentHLH hemophagocytic lymphohistiocytosislaw.invention03 medical and health sciences0302 clinical medicinelawInternal medicineGC glucocorticoidEpidemiologymedicine030212 general & internal medicineSurvival analysislcsh:R5-920Hemophagocytic lymphohistiocytosisID immunosuppressive drugbusiness.industryMortality ratemedicine.diseaseICU intensive care unitIntensive care unitIVIG intravenous immunoglobulinImmunosuppressive drug030220 oncology & carcinogenesisCohortEtiologylcsh:Medicine (General)businessNK natural killerMayo Clinic proceedings. Innovations, qualityoutcomes
researchProduct

Characteristics and management of primary and other immune thrombocytopenias: Spanish registry study

2017

The natural history and its modulation by treatments administered for immune thrombocytopenia (ITP) in the clinical practice remains unknown. In addition, little information is available on the characteristics and management of ITP in Spain. We conducted an observational, multicenter, registry in 70 Hematology Services from Spain between 2009 and 2011, which included children from 2 months of age and adults with primary ITP or another ITP diagnosed within the last 6 months (platelet count [PC]  484 patients were included (median [Q1, Q3] age 52 [29,74] years, 87.6% adults), 56% women, 10.5% with secondary ITP. Median (Q1, Q3) PC at diagnosis was 12 × 109/l (4, 32); 72% of patients had bleed…

MalePediatricsRegistry studyComorbidity030204 cardiovascular system & hematologycorticosteroids0302 clinical medicineAdrenal Cortex Hormonesimmune system diseaseshemic and lymphatic diseasesRegistriesChildresponseHematologyDisease ManagementImmunoglobulins IntravenousHematologyMiddle AgedClinical PracticeNatural historyPhenotypeTreatment OutcomeIntravenous ImmunoglobulinsChild PreschoolFemaleAlgorithmsAdultmedicine.medical_specialtyAdolescentHemorrhageintravenous immunoglobulinsYoung Adult03 medical and health sciencesImmune systemInternal medicinemedicineHumansAgedPurpura Thrombocytopenic IdiopathicPlatelet Countbusiness.industryInfantImmune thrombocytopeniaImmune thrombocytopeniaSpainObservational studybusinessBiomarkers030215 immunologyHematology
researchProduct

Brainstem Auditory Evoked Potentials and Visual Potentials in Kawasaki Disease: An Observational Monocentric Study

2020

Background: Kawasaki Disease is a systemic vasculitis, particularly involving coronary arteries. Rare involvement of other vascular districts is described, as central nervous system arteries, leading to a vasculitic neuropathy. Sensorineural hearing loss and alterations of evoked potentials are uncommonly reported complications.Methods: In an observational monocentric study, 59 children (37 males; 22 females; mean age: 2.7 ± 2.2 years) with documented Kawasaki Disease were enrolled. No risk factors for hearing loss and/or neurological impairment were identified in the cohort. Brainstem auditory evoked potentials and visual evoked potentials were correlated with clinical, hamatological and r…

medicine.medical_specialtygenetic structuresHearing lossvisual evoked potentialsCentral nervous systemintravenous immunoglobulinscoronary artery lesionPediatrics03 medical and health sciences0302 clinical medicine030225 pediatricsInternal medicineintravenous immunoglobulinmedicinekawasaki diseasePathologicalOriginal Researchbusiness.industrylcsh:RJ1-570lcsh:Pediatricscoronary artery lesionsmedicine.diseaseCoronary arteriesmedicine.anatomical_structurePediatrics Perinatology and Child Healthbrainstem auditory evoked potentialCardiologyKawasaki diseaseSensorineural hearing lossBrainstemmedicine.symptomvisual evoked potentialbusinessbrainstem auditory evoked potentials030217 neurology & neurosurgeryArteryFrontiers in Pediatrics
researchProduct

Kawasaki disease: Guidelines of Italian Society of Pediatrics, part II - Treatment of resistant forms and cardiovascular complications, follow-up, li…

2018

Abstract This second part of practical Guidelines related to Kawasaki disease (KD) has the goal of contributing to prompt diagnosis and most appropriate treatment of KD resistant forms and cardiovascular complications, including non-pharmacologic treatments, follow-up, lifestyle and prevention of cardiovascular risks in the long-term through a set of 17 recommendations. Guidelines, however, should not be considered a norm that limits the treatment options of pediatricians and practitioners, as treatment modalities other than those recommended may be required as a result of peculiar medical circumstances, patient’s condition, and disease severity or individual complications.

MaleDrug ResistanceReviewCoronary Artery Disease030204 cardiovascular system & hematologySeverity of Illness IndexCoronary artery diseaseEfficacy0302 clinical medicineCardiovascular Diseasecoronary artery abnormalitiesChildCoronary artery abnormalitieSocieties MedicalPediatricAnti-Inflammatory Agents Non-Steroidallcsh:RJ1-570Immunoglobulins IntravenousSettore MED/38Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICACardiovascular DiseasesInnovative biotechnologieChild PreschoolPractice Guidelines as TopicFemaleRisk assessmentmedicine.drugHumanmedicine.medical_specialtypediatricsMucocutaneous Lymph Node SyndromeRisk AssessmentFollow-Up Studie03 medical and health sciencesinnovative biotechnologies030225 pediatricsDiabetes mellitusSeverity of illnessmedicineHumansIntensive care medicineIntravenous immunoglobulinAspirinKawasaki diseasebusiness.industryWarfarinlcsh:Pediatricsmedicine.diseasePersonalized medicineInfliximabAspirin; Child; Coronary artery abnormalities; Innovative biotechnologies; Intravenous immunoglobulin; Kawasaki disease; Personalized medicine;Immunoglobulins IntravenouPediatrics Perinatology and Child Healthperinatology and child healthKawasaki diseaseaspirin; child; coronary artery abnormalities; innovative biotechnologies; intravenous immunoglobulin; Kawasaki disease; personalized medicine; pediatrics perinatology and child healthbusinessFollow-Up Studies
researchProduct

Efficacy and Safety of IQYMUNE®, a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia

2018

Background: Intravenous immunoglobulin (IVIG) IQYMUNE® is a highly purified 10% IVIG that was assessed using the new stringent definition of response described in the revised guideline on the clinical investigation of IVIG. The efficacy and the safety of IQYMUNE® were investigated in adult patients with chronic primary immune thrombocytopenia (ITP). Methods: In this phase III multinational, multicentre, prospective, uncontrolled, open-label, single-arm study, adult patients with a baseline platelet count < 30 × 10 9 /L were treated with IVIG 10% at a dose of 2 g/kg body weight administered over 2 consecutive days. The primary endpoint was Response over the study period and was defined accor…

medicine.medical_specialtyEuropean Medicines Agency guidelinesPlatelet countRenal functionHigh dose030204 cardiovascular system & hematologyGastroenterology03 medical and health sciencesIntravenous immunoglobulin; High dose; Immune thrombocytopenia; Response; European Medicines Agency guidelines; Platelet count; Bleeding assessment; Infusion rate0302 clinical medicineInfusion rateInternal medicinemedicineClinical endpointPlateletAdverse effectIntravenous immunoglobulinbiologybusiness.industryResponseGuidelineImmune thrombocytopeniaImmune thrombocytopenia030220 oncology & carcinogenesisConcomitantbiology.proteinBleeding assessmentOriginal ArticleAntibodybusinessJournal of Hematology
researchProduct

Ten-month follow-up of patients with covid-19 temporally related multi-system inflammatory syndrome in children: the experience of the children hospi…

2023

Abstract Background In Sicily, the first wave of COVID-19 showed a low epidemic impact in paediatric population, while the second and the third waves had a higher impact on clinical presentation of COVID-19 in children and a significantly higher severe outcome in patients with multisystem inflammatory syndrome in children (MIS-C), with a frequent life-threatening progression. Methods We describe a cohort of 22 Sicilian children (11 M; 11 F; age: 1.4–14 years), presenting with clinical features compatible with MIS-C. Patients with negative swab had a history of recent personal or parental infection. Results The following diagnostic criteria were detected: fever (100%); cheilitis and/or phary…

Settore MED/38 - Pediatria Generale E SpecialisticaGeneral MedicineCOVID-19 Intravenous immunoglobulin Kawasaki disease Methylprednisolone Multisystem inflammatory syndrome in children (MIS-C) SARS-CoV-2Italian Journal of Pediatrics
researchProduct

Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I - definition, epidemiology, etiopathogenesis, clinical expression and manag…

2018

Abstract The primary purpose of these practical guidelines related to Kawasaki disease (KD) is to contribute to prompt diagnosis and appropriate treatment on the basis of different specialists’ contributions in the field. A set of 40 recommendations is provided, divided in two parts: the first describes the definition of KD, its epidemiology, etiopathogenetic hints, presentation, clinical course and general management, including treatment of the acute phase, through specific 23 recommendations. Their application is aimed at improving the rate of treatment with intravenous immunoglobulin and the overall potential development of coronary artery abnormalities in KD. Guidelines, however, should…

MalePediatricsReviewPediatricsSeverity of Illness Index0302 clinical medicineRetrospective StudieEpidemiology030212 general & internal medicineDisease management (health)Coronary artery abnormalitieChildrenSocieties MedicalRandomized Controlled Trials as TopicPediatriclcsh:RJ1-570Disease ManagementImmunoglobulins IntravenousGeneral MedicinePrognosisSettore MED/38Treatment OutcomeSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAItalyMeta-analysisAcute DiseasePractice Guidelines as TopicDisease ProgressionFemaleCoronary artery abnormalitiesAspirin; Children; Coronary artery abnormalities; Intravenous immunoglobulin; Kawasaki disease;Humanmedicine.medical_specialtyPrognosiMucocutaneous Lymph Node SyndromeRisk Assessment03 medical and health sciences030225 pediatricsSeverity of illnessmedicineHumansRisk factorIntravenous immunoglobulinRetrospective Studiesaspirin; children; coronary artery abnormalities; intravenous immunoglobulin; Kawasaki disease; pediatrics perinatology and child healthAspirinKawasaki diseasebusiness.industrylcsh:PediatricsRetrospective cohort studymedicine.diseaseImmunoglobulins IntravenouPediatrics Perinatology and Child Healthperinatology and child healthKawasaki diseaseDifferential diagnosisbusiness
researchProduct